In Vivo Activity of Nisin A and Nisin V Against Listeria Monocytogenes in Mice

Overview

Journal BMC Microbiol

Publisher Biomed Central

Specialty Microbiology

Date 2013 Feb 5

PMID 23374279

Citations 29

Authors

Alicia Campion

Pat G Casey

Des Field

Paul D Cotter

Colin Hill

R Paul Ross

Affiliations

Soon will be listed here.

Abstract

Background: Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo.

Results: Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model.More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 10(5) cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen.

Conclusion: This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.

Citing Articles

A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.

Wali A, Talath S, Sridhar S, Shareef J, Goud M, Rangraze I Curr Issues Mol Biol. 2024; 46(11):13223-13251.

PMID: 39590383 PMC: 11592628. DOI: 10.3390/cimb46110789.

Nisin Inhibition of Gram-Negative Bacteria.

Charest A, Reed E, Bozorgzadeh S, Hernandez L, Getsey N, Smith L Microorganisms. 2024; 12(6).

PMID: 38930612 PMC: 11205666. DOI: 10.3390/microorganisms12061230.

Bacteriocins: potentials and prospects in health and agrifood systems.

Reuben R, Torres C Arch Microbiol. 2024; 206(5):233.

PMID: 38662051 PMC: 11045635. DOI: 10.1007/s00203-024-03948-y.

Bacterial interactions on nutrient-rich surfaces in the gut lumen.

Chiang B, Vega G, Dunwoody S, Patnode M Infect Immun. 2024; 92(9):e0048023.

PMID: 38506518 PMC: 11384750. DOI: 10.1128/iai.00480-23.

Cesin, a short natural variant of nisin, displays potent antimicrobial activity against major pathogens despite lacking two C-terminal macrocycles.

Guo L, Wambui J, Wang C, Muchaamba F, Fernandez-Cantos M, Broos J Microbiol Spectr. 2023; :e0531922.

PMID: 37754751 PMC: 10581189. DOI: 10.1128/spectrum.05319-22.

References

Bierbaum G, Sahl H . Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol. 2009; 10(1):2-18. DOI: 10.2174/138920109787048616. View

Wiedemann I, Benz R, Sahl H . Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J Bacteriol. 2004; 186(10):3259-61. PMC: 400633. DOI: 10.1128/JB.186.10.3259-3261.2004. View

Cao L, Wu J, Xie F, Hu S, Mo Y . Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. J Dairy Sci. 2007; 90(8):3980-5. DOI: 10.3168/jds.2007-0153. View

Goldstein B, Wei J, Greenberg K, NOVICK R . Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. J Antimicrob Chemother. 1998; 42(2):277-8. View

Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I . In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Int J Food Microbiol. 2009; 133(3):225-33. DOI: 10.1016/j.ijfoodmicro.2009.05.005. View

Brumfitt W, SALTON M, Hamilton-Miller J . Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J Antimicrob Chemother. 2002; 50(5):731-4. DOI: 10.1093/jac/dkf190. View

de Vos W, Kuipers O, van der Meer J, Siezen R . Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria. Mol Microbiol. 1995; 17(3):427-37. DOI: 10.1111/j.1365-2958.1995.mmi_17030427.x. View

And H, Hoover D . Bacteriocins and their Food Applications. Compr Rev Food Sci Food Saf. 2021; 2(3):82-100. DOI: 10.1111/j.1541-4337.2003.tb00016.x. View

Kuipers O, Beerthuyzen M, Siezen R, de Vos W . Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem. 1993; 216(1):281-91. DOI: 10.1111/j.1432-1033.1993.tb18143.x. View

10.

Carroll J, Field D, OConnor P, Cotter P, Coffey A, Hill C . Gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng Bugs. 2011; 1(6):408-12. PMC: 3056091. DOI: 10.4161/bbug.1.6.13642. View

11.

Brand A, de Kwaadsteniet M, Dicks L . The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Lett Appl Microbiol. 2010; 51(6):645-9. DOI: 10.1111/j.1472-765X.2010.02948.x. View

12.

Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S . Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. Antimicrob Agents Chemother. 2011; 55(4):1671-6. PMC: 3067139. DOI: 10.1128/AAC.01288-10. View

13.

Piper C, Casey P, Hill C, Cotter P, Ross R . The Lantibiotic Lacticin 3147 Prevents Systemic Spread of Staphylococcus aureus in a Murine Infection Model. Int J Microbiol. 2012; 2012:806230. PMC: 3265090. DOI: 10.1155/2012/806230. View

14.

Foulston L, Bibb M . Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Proc Natl Acad Sci U S A. 2010; 107(30):13461-6. PMC: 2922176. DOI: 10.1073/pnas.1008285107. View

15.

Severina E, SEVERIN A, Tomasz A . Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. J Antimicrob Chemother. 1998; 41(3):341-7. DOI: 10.1093/jac/41.3.341. View

16.

Piper C, Draper L, Cotter P, Ross R, Hill C . A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2009; 64(3):546-51. DOI: 10.1093/jac/dkp221. View

17.

Liu W, Hansen J . Some chemical and physical properties of nisin, a small-protein antibiotic produced by Lactococcus lactis. Appl Environ Microbiol. 1990; 56(8):2551-8. PMC: 184764. DOI: 10.1128/aem.56.8.2551-2558.1990. View

18.

Field D, Quigley L, OConnor P, Rea M, Daly K, Cotter P . Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microb Biotechnol. 2011; 3(4):473-86. PMC: 3815813. DOI: 10.1111/j.1751-7915.2010.00184.x. View

19.

Van Staden A, Brand A, Dicks L . Nisin F-loaded brushite bone cement prevented the growth of Staphylococcus aureus in vivo. J Appl Microbiol. 2012; 112(4):831-40. DOI: 10.1111/j.1365-2672.2012.05241.x. View

20.

Ingham A, Ford M, Moore R, Tizard M . The bacteriocin piscicolin 126 retains antilisterial activity in vivo. J Antimicrob Chemother. 2003; 51(6):1365-71. DOI: 10.1093/jac/dkg229. View